A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
Solid Tumor|Microsatellite Instability-High (MSI-H) Solid Tumors|Cutaneous Melanoma|Pancreatic Cancer|Breast Cancer (HR+HER2-)
DRUG: LY3300054|DRUG: Ramucirumab|DRUG: Abemaciclib|DRUG: Merestinib|DRUG: LY3321367
Number of Participants with LY3300054 Dose Limiting Toxicities (DLTs), Baseline through Cycle 1 (Approximately 28 Days)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3300054, Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months)|PK: Cmax of Ramucirumab, Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months)|PK: Cmax of Abemaciclib, Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months)|PK: Cmax of Merestinib, Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months)|PK: Cmax of LY3321367, Predose Cycle 1 Day 1 Through Follow Up (Approximately 6 Months)|Objective Response Rate (ORR): Proportion of Participants With a Complete Response (CR) or Partial Response (PR), Baseline to Measured Progressive Disease (Approximately 6 Months )|Progression Free Survival (PFS), Baseline to Measured Progressive Disease or Death (Approximately 12 Months)|Duration of Response (DoR), Date of CR or PR to Date of Measured Progressive Disease or Death Due to Any Cause (Approximately 12 Months)|Time to Response (TTR), Baseline to Date of CR or PR (Approximately 6 Months)|Disease Control Rate (DCR): Proportion of Participants who Exhibit Stable Disease (SD), CR or PR, Baseline to Measured Progressive Disease (Approximately 6 Months)
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.